Cardiovascular & Metabolic Diseases
Advancing next-generation solutions to improve the treatment of cardiometabolic conditions
Cardiometabolic diseases are some of the most complex common chronic conditions. These can include obesity, heart disease, stroke, diabetes, kidney disease and fatty liver disease. Cardiovascular diseases are the most common cause of death from non-communicable diseases and often have increased risk for comorbid conditions. Identifying and treating these conditions early can be critically important to helping people manage their health over their lifetime.
Our commitment to cardiometabolic research
Regeneron has a foundation in cardiometabolic research, with clinical studies for the treatment of high cholesterol dating back to 2009. We have been committed to researching both forms of inherited hypercholesterolemia through different mechanisms, including by using antibodies to target proteins that contribute to lipoprotein metabolism.
We approach early-stage research for cardiovascular and metabolic disease interventions in multiple ways. In obesity, we seek ways to improve the weight loss seen with GLP-1 and GIP inhibitors by exploring the potential of combination antibody approaches to impact muscle mass preservation, an important element of long-term health. We are also studying gene variants that have protective roles in obesity and associated conditions, such as metabolic dysfunction-associated steatohepatitis (MASH).
Separately, we are investigating a next-generation approach to anticoagulation with the goal of potential blood clot prevention with minimal bleeding.
It Takes a Village
Research that led to important discoveries for the treatment of dangerously high cholesterol